iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $440,136.46 in Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $10.03, for a total value of $440,136.46. Following the sale, the chief executive officer now owns 153,903 shares of the company's stock, valued at approximately $1,543,647.09. The trade was a 22.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michel Detheux also recently made the following trade(s):

• On Tuesday, June 10th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $439,707.66.
• On Monday, June 9th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.03, for a total value of $84,252.00.
• On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.21, for a total value of $448,035.22.
• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.21, for a total value of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $84,840.00.

iTeos Therapeutics Trading Up 1.9%

Shares of ITOS stock traded up $0.19 on Friday, hitting $10.17. 1,114,742 shares of the stock were exchanged, compared to its average volume of 673,504. The firm has a market capitalization of $389.25 million, a P/E ratio of -3.23 and a beta of 1.51. The business has a 50-day moving average of $7.84 and a 200 day moving average of $7.53. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. raised its holdings in iTeos Therapeutics by 74.4% during the first quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock worth $21,785,000 after acquiring an additional 1,556,798 shares in the last quarter. BVF Inc. IL raised its holdings in iTeos Therapeutics by 32.3% during the first quarter. BVF Inc. IL now owns 3,075,000 shares of the company's stock worth $18,358,000 after acquiring an additional 750,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after acquiring an additional 1,601,477 shares in the last quarter. 683 Capital Management LLC raised its holdings in iTeos Therapeutics by 90.6% during the first quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after acquiring an additional 831,883 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in iTeos Therapeutics by 15.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after acquiring an additional 163,880 shares in the last quarter. Institutional investors own 97.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Raymond James set a $12.00 target price on iTeos Therapeutics in a research note on Wednesday, May 14th. Leerink Partners reissued a "market perform" rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Wells Fargo & Company reissued an "equal weight" rating and issued a $12.00 target price (down from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. Finally, HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $15.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.